By B. Olivier. Case Western Reserve University.
Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular 100mg allopurinol with amex, metabolic buy generic allopurinol, and hemodynamic functioning buy generic allopurinol 100 mg. The effects of two aerobic training intensities on ambulatory blood pressure in hypertensive patients: results of a randomized trial order 300 mg allopurinol amex. Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology 2009 Oct; 4(10): 1565–1574. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Cardiovascular pharmacology of 3-n-butylphthalide in spontaneously hypertensive rats. Dietary, total body, and intracellular potassium-to-sodium ratios and their inﬂuence on cancer. Efﬁcacy of potassium and magnesium in essential hypertension: a double-blind, placebo- controlled, crossover study. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients. Age-related effects of placebo and active treatment in patients beyond the age of 60 years: the need for a proper control group. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Caffeine and stress: implications for risk, assessment, and management of hypertension. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Magnesium and blood pressure: review of the epidemiologic and clinical trial experience. Bioavailability of oral magnesium supplementation in female students evaluated from elimination of magnesium in 24-hour urine. Epidemiologic association between dietary calcium intake and blood pressure: a meta-analysis of published data. The inconsistent effects of calcium supplements upon blood pressure in primary hypertension. Calcium treatment of essential hypertension in elderly patients evaluated by 24 H monitoring. A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Blood pressure response to ﬁsh oil supplementation: metaregression analysis of randomized trials. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Oral arginine improves blood pressure in renal transplant and hemodialysis patients. Effects of oral L-arginine on plasma nitrate and blood pressure in cortisol- treated humans. Evaluation of the antihypertensive effect of L-arginine supplementation in patients with mild hypertension assessed with ambulatory blood pressure monitoring. Aging abolishes the renal response to L-arginine infusion in essential hypertension. Antihypertensive activity of “Katsuobushi Oligopeptide” in hypertensive and borderline hypertensive subjects. Antihypertensive activity of “Katsuobushi Oligopeptide” in hypertensive and borderline hypertensive subjects. Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolysate, on mild hypertensive subjects. Promising hypotensive effect of hawthorn extract: a randomized double- blind pilot study of mild, essential hypertension. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. Effectiveness and tolerability of a standardized extract from Hibiscus sabdariffa in patients with mild to moderate hypertension: a controlled and randomized clinical trial. Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Long-term effects of a plant-based dietary portfolio of cholesterol-lowering foods on blood pressure. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. Beneﬁcial effects of viscous dietary ﬁber from konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Dietary ﬁber and C-reactive protein: ﬁndings from national health and nutrition examination survey data. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Dose-response effects of omega-3 fatty acids on triglycerides, inﬂammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Fifteen year mortality in Coronary Drug Project patients: long-term beneﬁt with niacin. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. Lipoprotein responses to treatment with lovastatin, gemﬁbrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Effect of low-dose niacin on glucose control in patients with non–insulin-dependent diabetes mellitus and hyperlipidemia. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. A comparison of the efﬁcacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. The role of nicotinic acid and inositol hexaniacinate as anticholesterolemic and antilipemic agents. Impact of margarine enriched with plant sterols on blood lipids, platelet function, and fibrinogen level in young men. Effectiveness of long-term treatment with pantethine in patients with dyslipidemias.
A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure buy allopurinol 300 mg with mastercard. Continuous venove- nous haemodiafltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome- a multicentre randomised trial order allopurinol with american express. Dialysis in intensive care unit patients with acute kidney injury: continuous therapy is superior order 100 mg allopurinol with mastercard. Effcacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized con- trolled study allopurinol 100 mg without prescription. Binding to endothelial cells and macrophages leads to rapid internalization and depolymerization, whereas renal elimination is a much slower process. Given the many safe citrate protocols (see below), regional anticoagulation with heparin–protamin is nowadays not recommended anymore. They exhibit linear pharmacokinetics with stationary distribution volume and clearance processes, obviating the need of anti-Xa monitoring during continuous dosing. The drugs most frequently investigated are daltepa- rin, enoxaparin and nadroparin. This is termed heparin induced thrombocytopenia type 1, and the fall in peripheral platelet count is typically modest, and the platelet count recovers spontaneously. On the other hand heparin induced thrombocytopenia type 2 leads to marked thrombocytopenia (typically >50 % fall in peripheral platelet count) due to autoantibody mediated platelet activation which can be life-threatening, and necessitates heparin withdrawal to aid recovery . Heparins are large negatively charged proteoglycans which can nonspeciﬁcally bind to proteins. In the critically ill patient there are often many other potential causes of peripheral thrombocytopenia, ranging from reduced platelet production to increased consumption . The lower the platelets count the greater the risk of thrombosis and need for systemic anticoagulation. Typically thrombocytopenia starts to recover within 72 h fol- lowing heparin withdrawal, and if there is no response to heparin withdrawal, then an alternative explanation for thrombocytopenia should be considered. Currently systemic anticoagulation options include the direct thrombin inhibitor argatroban, and the hepa- rinoids, danaparoid and fondaparinux [25, 26]. Both danaparoid and fondaparinux are renally excreted and accumulate in patients with acute kidney injury and chronic kid- ney disease. Once the platelet count has recovered to >150,000 × 106/l, then warfarin therapy can be considered, as there is a risk of precipitating skin gangrene if warfarin ther- apy is started before the platelet count has recovered. Argatroban prolongs the pro- thrombin time, and therefore caution is required when converting patients from intravenous argatroban to oral warfarin therapy. Key Messages Heparin Induced Thrombocytopenia • Consider heparin induced thrombocytopenia in any patient with a 50 % fall in peripheral platelet count after starting heparin within the previous 10 days. At higher infusion doses it is also a potent smooth muscle relaxant and vasodilator. It is produced primarily in the endo- thelial and smooth muscle cells of blood vessels. Prostacyclin has a short half-life of 2–3 min with a clinical effect on end-organs and platelets of approximately 30 min [27 , 28]. Since prostacyclin exerts its effect on platelet function, it unlikely to be of signiﬁ- cant value in patients with severe thrombocytopenia. Although regional citrate anticoagulation has been shown to be more effective in maintaining hemoﬁlter patency, its use is often not possible as these patients are at risk of citrate accumulation as citrate is primarily metabolized in the liver . In this difﬁcult clinical situation, the use of prostacyclin may be valuable in prolonging hemoﬁlter life without adding extra risk of bleeding . It must be infused via a separate infusion line to avoid inactivation by acidic drugs such as catecholamine vasopressor agents. A similar issue may be seen using other infusion pumps that use peristaltic mechanisms. Since prostacyclin does not interfere with the coagula- tion systems, there is no simple clinical means of readily monitoring and titrating the infusion dose although thromboelastography could be used for this purpose . It has been shown to extend hemoﬁlter survival, par- ticularly when used in combination with low dose heparin [22–24 ]. The use of prostacyclin combined with regional anticoagulation with preﬁlter heparin and postﬁlter protamine has been studied in a prospective randomized trial and provided excellent ﬁlter survival and minimal bleeding when compared with conventional heparin . The main side effect of prostacyclin is hypotension caused by vasodilatation which may be managed by ensuring adequate ﬂuid volume status, by reducing the rate of infusion or by titrating a vasopressor infusion. Part of the citrate is removed by dialysis or ﬁltration, the remains enter the systemic circulation. Citrate is rapidly metabolized in the mitochondria, the che- lated calcium is released and the lost calcium is replaced. Citrate therefore provides regional anticoagulation and does not increase the risk of bleeding. The buffer strength is equivalent to 3 mmol bicarbonate per mmol citrate if all cations are sodium (trisodium citrate) and less so if part of the cations are hydrogen (citric acid). Citrate anticoagulation is better tolerated than heparin, and is associated with less bleeding and generally longer circuit survival. Its main risk is accumulation due to decreased metabolism as a result of liver failure or systemic hypoperfusion. Accumulation is characterized by a decrease in iCa, a rise in total Ca and metabolic acidosis. It is monitored by measuring systemic iCa (to adjust calcium replacement) and acid–base balance. It provides regional anticoagulation of the circuit, without increasing the patient’s risk of bleeding. Its anticoagulant properties are due to the chelation of ionized calcium (iCa) thereby causing hypocalcemia in the cir- cuit. Postﬁlter iCa can be monitored to ﬁne-tune anticagula- tion by adjusting citrate dose to iCa targets (0. The remains enter the patient’s circulation to be metabolized in the Krebs cycle of liver, kidney and muscle. The chelated calcium is released, while the calcium lost by dialysis or ﬁltration is replaced. Regional antico- agulation is the result, and this is the main beneﬁt of citrate [8, 36]. According to the classical concept, each mole of trisodium citrate provides a buffer equivalent of three moles of bicarbonate, if and when citrate is metabolized. This concept explains why the buffer strength of the citrate solution depends on the accompanying cation . In the latter, the bicarbonate is replaced by citrate and the solution is calcium-free [44–46]. When a separate sodium citrate solution is used, the associated dialysate or postdilution hemoﬁltra- tion solution contains no or less bicarbonate and less sodium to compensate for the citrate buffer and the sodium content of the citrate solution. Each protocol has strict rules for citrate dosing, acid base com- pensation and calcium replacement. These rules depend on the composition of the ﬂuids in use and cannot be generalized. The use of a strict protocol, adherence to the protocol and training are crucial for safety of the method. Chloride and lactate can be measured to monitor anion gap and tissue perfusion, but this is not obligatory. Citrate is metabolized in the mitochondria of liver, kidney and muscle and is decreased in patients with liver cir- rhosis  and systemic hypoperfusion. Citrate anticoagulation is even feasible in patients severe lactate acidosis due to metformine intoxication (personal experi- ence). Citrate is likely to accumulate in patients with persistent severe cardiogenic shock, ischemic hepatitis and poor muscle perfusion , because the Krebs cycle only operates under aerobic conditions. However, most critically ill patients tolerate citrate better than heparin [18 , 48]. Even in patients with liver failure, the use of citrate is feasible with intensiﬁed monitoring [49 ]. When citrate accumulates, iCa concentration in the patient’s blood falls, while total calcium rises due to chelation with citrate and replacement of calcium accord- ing to the protocol.
In a group of postmenopausal women order allopurinol 100 mg otc, supplementation with 250 to 750 mg per day of magnesium for 6 months followed by 250 mg per day for 6 to 18 months resulted in an increase in bone density in 71% of the women purchase allopurinol on line. Low zinc levels have been found in the serum and bone in people with osteoporosis order allopurinol 300mg without prescription. Manganese also stimulates the production of important compounds in the collagen matrix that provides a framework for the mineralization process cheap 100mg allopurinol. In animals, silicon-deﬁcient diets have produced abnormal skull development and growth retardation,118 and supplemental silicon partially prevented bone loss in female rats that had their ovaries removed. Folic Acid, Vitamin B6, and Vitamin B12 Accelerated bone loss in menopausal women may in part be due to increased levels of homocysteine, a breakdown product of methionine that will be elevated if folic acid, vitamin B6, or vitamin B12 levels are insufﬁcient. Homocysteine has the potential to promote osteoporosis if it is not eliminated adequately. In a prospective study, women with high homocysteine levels had almost twice as high a risk of nonvertebral osteoporotic fractures as women with low homocysteine levels. Restoration of the proper status of these B vitamins will bring elevated homocysteine levels down. Deficiencies of at least one of these nutrients are common in postmenopausal women. Vitamin C Vitamin C promotes the formation and cross-linking of some of the structural proteins in bone. Animal studies have shown that vitamin C deﬁciency can cause osteoporosis,122 and it has been known for decades that scurvy, a disease caused by vitamin C deﬁciency, is also associated with abnormalities of bone. Vitamin K Vitamin K, as discussed above, is required for the production of the bone protein osteocalcin, a key component in the matrix of bone. Studies of the effects of vitamin K supplementation on bone health have produced mixed results. Strontium Strontium is a nonradioactive earth element physically and chemically similar to calcium. Strontium ranelate is the speciﬁc strontium salt used in clinical trials for osteoporosis, but this form of strontium is not available in the United States. In a two-year trial, 353 postmenopausal women with osteoporosis and a history of at least one vertebral fracture received a placebo or one of three different doses of strontium: 170 mg per day, 340 mg per day, or 680 mg per day. In addition, since there are potential adverse effects with strontium, including rickets, bone mineralization defects, and interference with vitamin D metabolism, it makes sense to use the lowest dosage possible. There are many questions to be answered about strontium, including whether strontium chloride (the most common form of strontium used in U. Until these questions are answered, our advice is to consider supplementation with any strontium salt only as a last resort for elderly women who are at extremely high risk for fractures or who have a significant history of fractures. Ipriflavone Ipriﬂavone is a semisynthetic isoﬂavonoid, similar in structure to soy isoﬂavones, that has been approved in Japan, Hungary, and Italy for the treatment and prevention of osteoporosis. The compound, ipriﬂavone, has shown impressive results in a number of clinical studies. For example, in one study, ipriflavone (200 mg three times per day) increased bone density measurements by 2% and 5. Given the protective effect of soy isoﬂavones against breast cancer, the regular consumption of soy foods is encouraged. The mechanism of action appears to involve the enhancement of the effect of calcitonin on calcium metabolism (see above), as ipriflavone exerts no estrogen-like effects. Bone density was measured in the spine, hip, and forearm, as were biochemical markers of bone resorption. After 36 months of treatment, the annual percentage change in bone mineral density did not differ signiﬁcantly between the two groups. The number of women with new spinal fractures was the same in the two groups at all points in the 36 months. Unexpected results included decreased lymphocytes (a type of white blood cell) in the blood in 31 women treated with ipriflavone. So why did earlier studies of early and later postmenopausal women and of women with osteoporosis show positive results with ipriﬂavone and not this study? The most likely explanation is that the study population could have been too osteoporotic to show any beneﬁt. Or it could be that this ipriflavone study, the largest and best-designed to date, reveals that ipriflavone just does not have a signiﬁcant role in the treatment of osteoporosis. And why did ipriflavone cause a decrease in lymphocytes in this study but not in others? Subsequent studies done with ipriﬂavone since 2001 have demonstrated very positive results with no significant side effects. If you choose to use ipriﬂavone, monitor blood lymphocyte levels on a quarterly basis to detect any adverse effect. Botanical Medicines Green Tea Population-based studies as well as experimental studies have demonstrated that consumption of green tea (Camellia sinensis) may offer signiﬁcant protection against osteoporosis. In order to take advantage of this protection you need to drink three to ﬁve cups per day, providing a minimum of 250 mg per day of polyphenols (also referred to as catechins); alternatively, take a green tea extract providing the same level of polyphenols. In the experimental studies, the basic mechanism of green tea polyphenols was to impair bone resorption while at the same time stimulating osteoblast activity. The risk of developing osteoporosis may be reduced by optimizing peak bone mass in the younger years and minimizing subsequent bone loss with aging. In order to maximize peak bone mass (even in the context of hereditary and other nonmodiﬁable risk factors), a healthful lifestyle, proper nutrition, and moderate exercise should begin during childhood and adolescence and continue into adulthood. For women (and men) who have already been diagnosed with osteoporosis, drug therapies can serve as a short-term adjunct to the recommendations in this chapter if required. But there is no question that the nutritional and lifestyle factors recommended here should serve as the primary approach to slow bone loss and decrease the risk of fractures. Lifestyle • Weight-bearing exercise four times a week plus strength training two or more times a week • Fewer than seven alcoholic drinks per week; no more than two per day • Avoidance of smoking and secondhand smoke Diet The guidelines discussed in the chapter “A Health-Promoting Diet” are very much indicated in helping to build strong healthy bones. A key area of attention is getting adequate protein, soy isoﬂavones, and green leafy vegetables each day while limiting the intake of factors that promote calcium excretion, such as salt, sugar, excessive protein, and soft drinks. Parkinson’s disease affects more than 7 million people worldwide and at least 1 million in the United States, where about 50,000 new cases are reported annually. The average age of onset is approximately 60 and the prevalence increases with age. The damaged cells are the ones needed to produce the neurotransmitter called dopamine. In the early stages the tremors are more apparent while the person is at rest, such as while sitting or standing, and are less noticeable when the hand or limb is being used. A typical early symptom of Parkinson’s disease is “pill rolling,” in which the person appears to be rolling a pill back and forth between the ﬁngers. In many cases, the disease causes a permanent rigid, stooped posture and an unblinking, fixed expression. Many of the underlying issues in Parkinson’s disease are discussed in the chapter “A Cellular Approach to Health,” and that chapter also provides a deeper understanding of the preventive and therapeutic strategies that are important in Parkinson’s disease. The ﬁrst biochemical abnormality in Parkinson’s disease is a decrease in the level of glutathione, the brain cell’s primary antioxidant. Low glutathione makes the cells more susceptible to oxidative damage, such as that caused by environmental toxins. Population-based studies and animal experimental models have identiﬁed an association between Parkinson’s disease and a number of environmental factors, including living in a rural area, farming, drinking well water, exposure to pesticides, and long-term occupational exposure to copper, iron, lead, and manganese. In other words, it may be the total load of neurotoxins—instead of any single agent—that matters in the development of Parkinson’s. What all of these environmental toxins have in common is that they cause depletion of glutathione and disruption of the mitochondrial function. By the time Parkinson’s disease is typically diagnosed, more than 50% of the substantia nigra has been destroyed. Therapeutic Considerations At this point in time, Parkinson’s disease is best treated with drug therapy along with key dietary, nutritional, and herbal recommendations to address the underlying disease process and/or enhance the effectiveness of drug therapy. The most popular drug used in Parkinson’s disease is Sinemet, which contains two key ingredients: levodopa and carbidopa. Levodopa, or L-dopa, is the “middle step” in the conversion of the amino acid tyrosine into dopamine. Carbidopa is a drug that works by ensuring that more L-dopa is converted to dopamine within the brain, where it is needed, and not within the other tissues of the body. Other drugs used include Eldepryl (selegiline or deprenyl), bromocriptine, and amantadine.